Keyphrases
Double-blind Randomized Controlled Trial
100%
COVID-19
100%
Transmembrane Protease Serine 2 (TMPRSS2)
100%
Camostat Mesylate
100%
Camostat
75%
Placebo Groups
75%
Time to Clinical Improvement
50%
Adverse Events
50%
Viral Load
50%
Placebo
50%
30-day Mortality
50%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
25%
Confidence Interval
25%
Ordinal Scale
25%
Oropharyngeal
25%
Cell Infection
25%
Hazard Ratio
25%
Clinical Improvement
25%
EudraCT
25%
Non-associated
25%
Median Time
25%
Time to Discharge
25%
Investigator-initiated
25%
Multicenter Trial
25%
Hospitalization
25%
Cell Entry
25%
Randomized Trial
25%
ICU Mortality
25%
Randomized Placebo-controlled Trial
25%
ICU Admission
25%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Coronavirinae
100%
Randomized Controlled Trial
100%
Placebo
100%
Camostat Mesilate
100%
Serine Proteinase
100%
Camostat
50%
Infection
33%
SARS Coronavirus
33%
Adverse Event
33%